Compugen (NASDAQ:CGEN) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS

Compugen (NASDAQ:CGEN) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.14), Zacks reports. Compugen had a net margin of 2.67% and a return on equity of 2.62%. The company had revenue of $1.47 million for the quarter, compared to analysts’ expectations of $17.47 million.

Compugen Trading Down 7.2 %

Shares of Compugen stock opened at $1.68 on Wednesday. The company has a fifty day moving average price of $2.04 and a 200 day moving average price of $1.84. Compugen has a twelve month low of $1.35 and a twelve month high of $3.03. The stock has a market cap of $149.92 million, a price-to-earnings ratio of 84.00 and a beta of 2.65.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer initiated coverage on shares of Compugen in a research report on Monday, January 13th. They set an “outperform” rating and a $4.00 price target for the company.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.